Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 15Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Follicular 6Lymphoma 5Multiple Myeloma 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Lymphoma, Mantle-Cell 3Hodgkin Disease 3Breast Neoplasms 3Recurrence 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Lymphoma, T-Cell, Peripheral 2Hematologic Neoplasms 2Endometrial Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thrombocytosis 1Stomach Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rectal Neoplasms 1Primary Myelofibrosis 1Ovarian Neoplasms 1Osteosarcoma 1

Interventions

Cyclophosphamide 73fludarabine phosphate 42Filgrastim 38Peripheral Blood Stem Cell Transplantation 35Radiotherapy 33Cyclosporine 32Busulfan 32Mycophenolic Acid 30Etoposide 29Antilymphocyte Serum 28Whole-Body Irradiation 26Methotrexate 25Melphalan 21Methylprednisolone 20Rituximab 19Vincristine 17Tacrolimus 17Cytarabine 17Cord Blood Stem Cell Transplantation 17Doxorubicin 14Prednisone 13Thiotepa 10Granulocyte Colony-Stimulating Factor 9Leucovorin 7Carboplatin 7fludarabine 6aldesleukin 6sargramostim 5Sirolimus 5Psychiatric Rehabilitation 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Dendritic Cell Sarcoma, Interdigitating × copanlisib × Lymphoid × Clear all
NCT03886649 2022-04-01

Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.

Swiss Cancer Institute

Phase 1 Terminated
7 enrolled
LymphoidSarcoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡